PXN and salivary gland cancer: On the same line, Andisheh-Tadbir et al. [32] conducted a study to assess the tissue levels of paxillin in several salivary gland cancers, and they discovered that its greatest levels were detected in tumoral tissues compared to control, but its expression was not connected with the patients’ clinicopathological features.